Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
Status:
Not yet recruiting
Trial end date:
2024-12-17
Target enrollment:
Participant gender:
Summary
Based on the population pharmacokinetic data of Chinese patients with atrial fibrillation,
the study will evaluate the suitability of the ENGAGE PopPK model of edoxaban in patients
with atrial fibrillation in China, and build a predictive dose model of edoxaban that meets
the characteristics of Chinese people. It can provide perfect individualized dosing plan
improves clinical efficacy and reduces adverse drug reactions.
Phase:
Phase 4
Details
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborator:
Chinese Academy of Medical Sciences, Fuwai Hospital